Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use
暂无分享,去创建一个
L. Pagano | F. Aversa | M. Luppi | L. Romani | G. Rossi | A. Nosari | A. Venditti | A. Busca | C. Girmenia | A. Novelli | S. Cesaro | A. Candoni
[1] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[2] K. Takemoto,et al. AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy , 2017, Journal of liposome research.
[3] L. Pagano,et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients , 2016, Haematologica.
[4] H. Einsele,et al. Common Genetic Polymorphisms within NFκB-Related Genes and the Risk of Developing Invasive Aspergillosis , 2016, Front. Microbiol..
[5] M. Ruhnke,et al. Recent developments in the management of invasive fungal infections in patients with oncohematological diseases , 2016, Therapeutic advances in hematology.
[6] David W. Henry,et al. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[7] J. Turnidge,et al. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. , 2016, Revista iberoamericana de micologia.
[8] N. Stone,et al. Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions , 2016, Drugs.
[9] M. Melhem,et al. SUSCEPTIBILITY TEST FOR FUNGI: CLINICAL AND LABORATORIAL CORRELATIONS IN MEDICAL MYCOLOGY , 2015, Revista do Instituto de Medicina Tropical de Sao Paulo.
[10] D. Perlin. Mechanisms of echinocandin antifungal drug resistance , 2015, Annals of the New York Academy of Sciences.
[11] S. Seyedmousavi,et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[12] P. Hauser,et al. Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus , 2015, Emerging infectious diseases.
[13] J. Buer,et al. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. , 2015, The Journal of antimicrobial chemotherapy.
[14] L. Pagano,et al. Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data , 2015, Journal of chemotherapy.
[15] D. Falci,et al. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real‐life study , 2015, Mycoses.
[16] D. Falci,et al. Hematological toxicities associated with amphotericin B formulations , 2015, Leukemia & lymphoma.
[17] I. Raad,et al. Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy. , 2014, The Journal of antimicrobial chemotherapy.
[18] M. Proschan,et al. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[19] A. Venteicher,et al. Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess , 2014, Journal of Clinical Neuroscience.
[20] D. Sperl,et al. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. , 2014, The Journal of antimicrobial chemotherapy.
[21] D. Kamiński. Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments , 2014, European Biophysics Journal.
[22] E. Roilides,et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. , 2014, The Lancet. Oncology.
[23] P. Chiusolo,et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] A. Mantovani,et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. , 2014, The New England journal of medicine.
[25] R. Fanin,et al. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real‐life combo study , 2013, Mycoses.
[26] J. Guarro,et al. Efficacy of intrathecal liposomal amphotericin B plus oral posaconazole in the treatment of acute meningeal cryptococcosis in a murine model. , 2013, International journal of antimicrobial agents.
[27] F. V. van Tiel,et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] L. Pagano,et al. Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[29] R. Hamill. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity , 2013, Drugs.
[30] L. Pagano,et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries , 2013, Haematologica.
[31] C. M. Oliveira,et al. Diagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B , 2013, Clinical Drug Investigation.
[32] Kieren A Marr,et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. , 2012, The Journal of infection.
[33] G. Barratt,et al. Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity. , 2012, International journal of pharmaceutics.
[34] Dan Peer,et al. Altering the immune response with lipid-based nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[35] A. Erbacher,et al. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis , 2012, BMC Infectious Diseases.
[36] G. Ippolito,et al. Immunoglobulin Analysis Tool: A Novel Tool for the Analysis of Human and Mouse Heavy and Light Chain Transcripts , 2012, Front. Immun..
[37] Ó. Zaragoza,et al. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug , 2012, Front. Microbio..
[38] F. Aversa,et al. Immunity and Tolerance to Fungi in Hematopoietic Transplantation: Principles and Perspectives , 2012, Front. Immun..
[39] B. Posteraro,et al. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies. , 2012, International journal of antimicrobial agents.
[40] M. Netea,et al. Molecular view on PRR cross‐talk in antifungal immunity , 2012, Cellular microbiology.
[41] J. Guarro,et al. Efficacy of intrathecal administration of liposomal amphotericin B combined with voriconazole in a murine model of cryptococcal meningitis. , 2012, International journal of antimicrobial agents.
[42] M. Sanz,et al. Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination , 2012, Mediterranean journal of hematology and infectious diseases.
[43] B. Spellberg,et al. Combination therapy for mucormycosis: why, what, and how? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] S. Cesaro,et al. Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients , 2012, Pediatric reports.
[45] K. Bochennek,et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[46] Nina Singh,et al. Immune reconstitution syndrome and fungal infections , 2011, Current opinion in infectious diseases.
[47] C. Heussel,et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation , 2011, British journal of haematology.
[48] F. V. van Tiel,et al. Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009 , 2011, Emerging infectious diseases.
[49] M. Hellmich,et al. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study. , 2011, The Journal of hospital infection.
[50] J. Briones,et al. Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution , 2011, Bone Marrow Transplantation.
[51] F. Aversa,et al. Immunogenetic Profiling to Predict Risk of Invasive Fungal Diseases: Where Are We Now? , 2011, Immunological investigations.
[52] J. Dipersio,et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. , 2010, Blood.
[53] I. Raad,et al. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? , 2010, Cancer.
[54] S. Ranque,et al. Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study. , 2010, Hematology/oncology and stem cell therapy.
[55] H. Matsubara,et al. Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome). , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[56] M. Shivaprakash,et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study , 2010, Bone Marrow Transplantation.
[57] F. Regateiro,et al. Connecting the mechanisms of T‐cell regulation: dendritic cells as the missing link , 2010, Immunological reviews.
[58] C. Lass‐Flörl. In vitro susceptibility testing in Aspergillus species: an update. , 2010, Future microbiology.
[59] G. Jensen,et al. Pharmacokinetics and Pharmacodynamics of Amphotericin B Deoxycholate, Liposomal Amphotericin B, and Amphotericin B Lipid Complex in an In Vitro Model of Invasive Pulmonary Aspergillosis , 2010, Antimicrobial Agents and Chemotherapy.
[60] Giuseppe Leone,et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study , 2010, Haematologica.
[61] Margarida Saraiva,et al. The regulation of IL-10 production by immune cells , 2010, Nature Reviews Immunology.
[62] L. Pagano,et al. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. , 2010, Blood reviews.
[63] N. Oku,et al. Temperature-dependent transfer of amphotericin B from liposomal membrane of AmBisome to fungal cell membrane. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[64] M. Shivaprakash,et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. , 2009, The Journal of antimicrobial chemotherapy.
[65] D. Denning,et al. zole-resistance in Aspergillus: Proposed nomenclature and breakpoints , 2009 .
[66] F. Aversa,et al. Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. , 2009, Experimental hematology.
[67] D. Denning,et al. Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure , 2009, Emerging infectious diseases.
[68] A. Vekhoff,et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[69] J. Cleary,et al. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B. , 2009, Clinical advances in hematology & oncology : H&O.
[70] H. Einsele,et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT , 2009, Bone Marrow Transplantation.
[71] F. Morell,et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[72] D. Denning,et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[73] G. Verhoef,et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients , 2009, Cancer.
[74] M. Ghannoum,et al. In Vitro Activity of Amphotericin B Against Aspergillus terreus Isolates from Different Countries and Regions , 2008, Journal of chemotherapy.
[75] David S Schneider,et al. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases , 2008, Nature Reviews Immunology.
[76] M. Fiegl,et al. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients , 2008, Annals of Hematology.
[77] D. Marriott,et al. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders , 2008, Internal medicine journal.
[78] F. Lanternier,et al. Liposomal amphotericin B: what is its role in 2008? , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[79] M. Ellis. New dosing strategies for liposomal amphotericin B in high-risk patients. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[80] W. Steinbach,et al. Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases , 2008, Pediatrics.
[81] J. Adler-Moore,et al. Amphotericin B lipid preparations: what are the differences? , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[82] D. Andes,et al. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. , 2008, Therapeutic drug monitoring.
[83] W. Couet,et al. Mechanism-Based Pharmacokinetic-Pharmacodynamic Models of In Vitro Fungistatic and Fungicidal Effects against Candida albicans , 2008, Antimicrobial Agents and Chemotherapy.
[84] R. Drew,et al. Antifungal serum concentration monitoring: an update. , 2007, The Journal of antimicrobial chemotherapy.
[85] L. Pagano,et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[86] U. Grohmann,et al. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation , 2007, Nature Reviews Immunology.
[87] R. Lewis. Pharmacodynamic implications for use of antifungal agents. , 2007, Current opinion in pharmacology.
[88] L. Pagano,et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[89] C. Heussel,et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[90] John W. Earl,et al. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases , 2007, European Journal of Clinical Pharmacology.
[91] D. Andes. Pharmacokinetics and pharmacodynamics of antifungals. , 2006, Infectious disease clinics of North America.
[92] C. Wiedermann,et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. , 2006, The Journal of antimicrobial chemotherapy.
[93] J. Mensa,et al. Prospective evaluation of procalcitonin in adults with non-neutropenic fever after allogeneic hematopoietic stem cell transplantation , 2006, Bone Marrow Transplantation.
[94] S. Holland,et al. Immunotherapy for fungal infections. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[95] V. Tam,et al. Pharmacodynamic Activity of Amphotericin B Deoxycholate Is Associated with Peak Plasma Concentrations in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis , 2006, Antimicrobial Agents and Chemotherapy.
[96] D. Andes,et al. Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models , 2006, Antimicrobial Agents and Chemotherapy.
[97] A. Vinks,et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[98] L. Huang,et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. , 2006, Blood.
[99] D. Kontoyiannis,et al. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[100] D. Kontoyiannis,et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis , 2005, Cancer.
[101] C. Lequaglie,et al. Penetration of Amphotericin B in Human Lung Tissue after Single Liposomal Amphotericin B (AmBisome) Infusion , 2005, Journal of chemotherapy.
[102] C. Montagnoli,et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. , 2005, The Journal of antimicrobial chemotherapy.
[103] G. Di Bonaventura,et al. In Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic Malignancies , 2004, Antimicrobial Agents and Chemotherapy.
[104] A. Mantovani,et al. Anti-Aspergillus fumigatus Efficacy of Pentraxin 3 Alone and in Combination with Antifungals , 2004, Antimicrobial Agents and Chemotherapy.
[105] L. Romani. Immunity to fungal infections , 2004, Nature Reviews Immunology.
[106] Thomas J Walsh,et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.
[107] J. Gavaldà,et al. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. , 2003, The Journal of antimicrobial chemotherapy.
[108] D. Golenbock,et al. The Antifungal Drug Amphotericin B Promotes Inflammatory Cytokine Release by a Toll-like Receptor- and CD14-dependent Mechanism* , 2003, Journal of Biological Chemistry.
[109] Russell E. Lewis,et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies , 2003, Cancer.
[110] K. Sepkowitz,et al. Refractory Aspergillus pneumonia in patients with acute leukemia , 2003, Cancer.
[111] H. Resat,et al. Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. , 2002, Biochimica et biophysica acta.
[112] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[113] T. Walsh,et al. Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans , 2002, Antimicrobial Agents and Chemotherapy.
[114] E. Anaissie,et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.
[115] H. Hof. Critical Annotations to the Use of Azole Antifungals for Plant Protection , 2001, Antimicrobial Agents and Chemotherapy.
[116] S. Piscitelli,et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. , 2000, The Journal of infectious diseases.
[117] M. Klepser,et al. Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.
[118] H. Lynch,et al. Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .
[119] A. Groll,et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. , 1996, The Journal of infection.
[120] R. Hay. Liposomal amphotericin B, AmBisome. , 1994, The Journal of infection.
[121] S. Khoo,et al. Administering amphotericin B--a practical approach. , 1994, The Journal of antimicrobial chemotherapy.
[122] R. Bittman,et al. Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols. , 1982, Biochimica et biophysica acta.
[123] R. A. Woods,et al. Polyene resistance and the isolation of sterol mutants in Saccharomyces cerevisiae. , 1972, Journal of general microbiology.
[124] Anil A Panackal. Combination Antifungal Therapy for Invasive Aspergillosis Revisited. , 2016, Medical mycology: open access.
[125] W. Melchers,et al. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. , 2015, The Journal of antimicrobial chemotherapy.
[126] J. Perfect. The impact of the host on fungal infections. , 2012, The American journal of medicine.
[127] N. Freemantle,et al. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. , 2011, The Journal of antimicrobial chemotherapy.
[128] K. Engels,et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. , 2010, The Journal of infection.
[129] Á. González-Fernández,et al. Nanoparticles and the immune system. , 2010, Endocrinology.
[130] D. Kontoyiannis,et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.
[131] G. Storm,et al. Current Topic : Fungal Infections Vol . 16 , No . 1 Eur , 2005 .
[132] R. Barbó,et al. Combination Antifungal Therapy for Invasive Aspergillosis , 2005 .
[133] M. Masiá Canuto,et al. Antifungal drug resistance to azoles and polyenes. , 2002, The Lancet. Infectious diseases.
[134] D. Ellis. Amphotericin B: spectrum and resistance. , 2002, The Journal of antimicrobial chemotherapy.
[135] B. Steinberg,et al. Amphotericins A and B: two new antifungal antibiotics possessing high activity against deep-seated and superficial mycoses. , 1955, Antibiotics annual.